Anavex Life Sciences’ (AVXL) Buy Rating Reiterated at D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $46.00 target price on the biotechnology company’s stock. D. Boral Capital’s price target indicates a potential upside of 374.23% from the company’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Tuesday, January 21st.

Anavex Life Sciences Trading Down 2.1 %

Anavex Life Sciences stock opened at $9.70 on Tuesday. The firm has a market capitalization of $822.72 million, a P/E ratio of -18.65 and a beta of 0.70. The stock has a fifty day moving average price of $9.98 and a 200 day moving average price of $7.51. Anavex Life Sciences has a 52 week low of $3.25 and a 52 week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. As a group, equities analysts predict that Anavex Life Sciences will post -0.73 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Nwam LLC acquired a new stake in shares of Anavex Life Sciences during the third quarter valued at approximately $5,172,000. Renaissance Technologies LLC boosted its position in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after purchasing an additional 386,537 shares during the last quarter. Barclays PLC raised its stake in shares of Anavex Life Sciences by 70.4% during the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock worth $882,000 after purchasing an additional 64,101 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Anavex Life Sciences by 2.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,883,199 shares of the biotechnology company’s stock valued at $10,699,000 after buying an additional 51,946 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Anavex Life Sciences in the second quarter worth approximately $191,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.